Le Lézard
Classified in: Health
Subjects: CCA, BFA, FVT

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DUBLIN, Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024, at 2:15 p.m. PST / 10:15 p.m. GMT.

A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available on the website for 30 days following the conference.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases?often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.


Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg 

These press releases may also interest you

at 09:15
Breaking, a plastic degradation and synthetic biology company, gestated at Colossal Biosciences based on a core discovery out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, launches today with the announcement of...

at 09:08
Woof, the award winning brand behind The Pupsicle, is proud to announce its newest (and tastiest) innovation yet - Wellness Pops. Reimagining the way pets access nutrition, Wellness Pops imbue essential nutrients into Pupsicle refill treats,...

at 09:07
Gresham Smith, a top-ranked national architecture and engineering firm with more than $328 million in annual gross revenue, announced today that Project Executive Corie Baker, AIA, LEED AP BD+C, EDAC, WELL AP, Fitwel Ambassador, has been selected as...

at 09:05
Grapheal, a deep-tech startup, in collaboration with the EDYTEM laboratory? a joint research unit of the French Research Center CNRS and Savoie Mont Blanc University? today announced the design of a portable device connected to smartphones capable of...

at 09:05
XP Health, a company dedicated to democratizing vision care with a digital-first vision benefits platform, announced today the formation of "20/20 VISIONaries: An XP Health Social Impact Initiative" a new program to combat childhood illiteracy....

at 09:03
Professional Transition Strategies (PTS), a company that facilitates dental practice purchases and mergers & acquisitions, is ecstatic to report it facilitated 30 practice transitions for dental entrepreneurs around the country in Q1 2024....

News published on and distributed by: